Thalidomide in the treatment of multiple myeloma

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Thalidomide - banned from clinical use in the 1960s because of severe teratogenicity - is now back in clinical practice as an effective agent in the treatment of relapsed and refractory multiple myeloma. Several clinical trials have determined that thalidomide is active in 25-35% of patients with relapsed myeloma. The role of thalidomide in early-stage myeloma is being actively investigated. Thalidomide has antiangiogenic and immunomodulatory properties and is an effective inhibitor of TNF-α. However, the mechanism of its action in myeloma remains unclear. Major toxicities of thalidomide include constipation, sedation, skin rash, fatigue and peripheral neuropathy. This paper summarizes the current status of thalidomide in multiple myeloma.

Original languageEnglish (US)
Pages (from-to)20-28
Number of pages9
JournalExpert review of anticancer therapy
Volume1
Issue number1
DOIs
StatePublished - Jan 1 2001

Keywords

  • Angiogenesis
  • Antiangiogenic therapy
  • Cancer
  • Multiple myeoma
  • Thalidomide
  • Treatment
  • VEGF
  • bFGF

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Thalidomide in the treatment of multiple myeloma'. Together they form a unique fingerprint.

  • Cite this